Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
GlobalData on MSN7d
Innovent Biologics doses first subject in trial of ovarian cancer therapyInnovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...
Vietnam Investment Review on MSN7d
Innovent Biologics: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian CancerSAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback